WINNIPEG, Manitoba - (February 21, 2005) Medicure Inc.
(TSX:MPH/Amex:MCU), a cardiovascular drug discovery
and development company, is pleased to announce that
President and Chief Executive Officer, Albert D. Friesen,
Ph.D., will be a featured panelist at a focus session
entitled "A Heart to Heart Discussion on Future
Cardiovascular Therapies" at the BIO CEO Investor
Conference, held on February 23 and 24, 2005 in New
York City.
On February 23, Dr. Friesen will participate in the
90-minute discussion along with three other prominent
biotech executives. This session will feature
presentations by each of the four invited cardiovascular
companies, highlighting their company's respective
initiatives and programs in the field of cardiovascular
medicine. In addition, there will also be commentary
from each panelist on the current regulatory environment
for cardiovascular drugs and what is on the horizon for
2005 and beyond. The session will also include a
30-minute Question & Answer period with the audience.
BIO CEO is considered one of industry's most important
annual investor conferences, bringing together
biotechnology CEOs, members of the financial
community and other key industry supporters to examine
investment opportunities and issues facing the industry.
For information on this Biotechnology Industry
Organization event, please visit www.bio.org and click on
the link: "BIO CEO & Investor Conference".
ABOUT MEDICURE INC.
Medicure Inc. is a cardiovascular drug discovery and
development Company focused on developing effective
therapeutics for unmet needs in the field of
cardiovascular medicine, the largest pharmaceutical
market sector. The Company's solid position in this field
is supported by the following attributes:
- Cardiovascular focused pipeline: a global market of
over US $70 billion
- Two drugs - MC-1 & MC-4232 - in advanced Phase II
trials
- Two positive Phase II trials completed
- Unique products addressing major markets not
adequately served by existing drugs
- Second combination product, MC-4262 is entering
development stage
- Dual action antithrombotic, MC-45308, in preclinical
testing
The Company's financial position remains solid,
providing sufficient resources to complete the ongoing
Phase II studies, and to advance the lead candidates up
to pivotal Phase III studies.
Medicure's medicinal chemistry based Drug Discovery
program is focused on discovery and advancement of
novel small molecule, anti-ischemics and
anti-thrombotics towards human clinical studies.
This news release contains forward-looking statements
that involve risks, which may cause actual results to differ
materially from the statements made, and accordingly
may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. The
forward-looking statements are made as of the date
hereof, and the Company disclaims any intention and
has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new
information, future events, or otherwise.
For more information, please contact:
Derek Reimer
Chief Financial Officer
Medicure Inc.
888-435-2220
204-488-9823 fax
info@medicure.com
Back to News Releases
